Through the acquisition of Vibalogics, Recipharm will expand its advanced therapy medicinal products (ATMPs) offering into virotherapies. The deal, of which financial details have not been disclosed, sees Swedish contract development manufacturing organization (CDMO) Recipharm acquire Vibalogics, a virotherapy CDMO. According to Recipharm, the deal expands their capabilities in biologics modalities and Vibalogics’ knowledge in viral vaccines, oncolytic viruses, and gene therapies will provide the firm with diverse technologies. “We are delighted to welcome our new colleagues from Vibalogics to…

Immunity Bio has leased a recently built US manufacturing facility from Athenex as part of an effort to expand its manufacturing capacity. The facility in Dunkirk, New York houses ISO Class 5 clean rooms for upstream and downstream manufacturing, as well as fill and finish and large-scale freeze-drying capabilities. Under the deal Immunity Bio will provide contract manufacturing capacity at the facility to Athenex. The lease agreement will see Immunity Bio pay Athenex $40 million according to reports in the…